Publications by authors named "Elwood C Massey"
Article Synopsis
- Using response rate as a primary objective in brain tumor studies is not ideal due to changing imaging criteria, so future research should focus on overall survival and account for common disease-related toxicities.
- In a study of BEV-naïve recurrent malignant glioma patients, the combination of rilotumumab and bevacizumab showed an objective response rate of 27.8% and a median overall survival of 11.2 months.
- Most treatment-related side effects were mild, but there were severe cases of venous thromboembolism, highlighting the importance of careful safety analysis for adverse events that may be common in brain tumor populations.
